Journal of Ocular Pharmacology and Therapeutics
译名:眼科药理学与治疗学杂志
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
1-3
2026
影响因子区间
—
平台估算
23%
2025
中国作者发文占比
40000000 IRR;600 USD
收费
期刊简介:Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders.Journal of Ocular Pharmacology and Therapeutics coverage includes:GlaucomaCataractsRetinal degenerationOcular infection, trauma, and toxicologyOcular drug delivery and biotransformationOcular pharmacotherapy/clinical trialsOcular inflammatory and immune disordersGene and cell-based therapiesOcular metabolic disordersOcular ischemia and blood flowProliferative disorders of the eyeEyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.
【译文】《眼科药理学和治疗学杂志》是唯一一本结合眼科和药理学领域的同行评审期刊,旨在实现眼科疾病和障碍的最佳治疗和预防。该杂志提供了治疗眼科疾病药物药代动力学和药效学的最新发现。该杂志的涵盖范围包括:青光眼、白内障、视网膜变性、眼部感染、创伤和毒理学、眼部药物递送和生物转化、眼部药物治疗/临床试验、眼部炎症和免疫疾病、基于基因和细胞的疗法、眼部代谢疾病、眼部缺血和血流、眼部增殖性疾病、关注药物发现——由Gary D. Novack博士撰写,介绍药物和设备管道的最新更新以及FDA的政策/监管变化。

| 指标 | 当前值 | 近三年趋势 |
|---|---|---|
| JCR分区 | Q2 | 暂无 |
| 中科院分区 | 4区 | 暂无 |
| 影响因子区间 | 1-3 | 暂无 |